CPB1: A Potential Drug Target and Biomarker for Pancreatic Cancer

Target Name: CPB1

NCBI ID: G1360

CPB1

CPB1: A Potential Drug Target and Biomarker for Pancreatic Cancer

Abstract:

Pancreatic cancer is a deadly form of cancer that affects millions of people worldwide. Despite advances in surgical and radiation treatments, the survival rate for pancreatic cancer remains poor. Therefore, there is a need for new therapeutic approaches to treat this disease. The proteinCPB1, which is expressed in high levels in pancreatic cancer cells, has been identified as a potential drug target and biomarker for pancreatic cancer. This article will review the current literature onCPB1, its expression in pancreatic cancer, and its potential as a drug target and biomarker.

Introduction:

Pancreatic cancer is a heterogeneous disease, with different subtypes that arise from various molecular mechanisms. Despite advances in surgical and radiation treatments, the survival rate for pancreatic cancer remains poor, with a 5-year survival rate of only around 15%. Therefore, there is a need for new therapeutic approaches to treat this disease.

The proteinCPB1 has been identified as a potential drug target and biomarker for pancreatic cancer.CPB1 is a 25-kDa transmembrane protein that is expressed in high levels in pancreatic cancer cells. It is a member of the Tetraspan family, which includes proteins that are involved in various cellular processes, including cell signaling, cell adhesion, and intracellular signaling.

Expression ofCPB1 in pancreatic cancer:

Studies have shown that CPB1 is expressed in high levels in pancreatic cancer cells. In pancreatic ductal adenocarcinoma (PDAC), the expression ofCPB1 was found to be significantly higher than in the surrounding normal tissue. This increased expression ofCPB1 was associated with poor prognosis in PDAC patients.

In addition, several studies have shown that high levels ofCPB1 expression are associated with pancreatic cancer progression and poor prognosis. For example, a study by Kim et al. found that high levels ofCPB1 expression were associated with poor prognosis in pancreatic cancer patients, with a 5-year survival rate of only around 12%.

Potential as a drug target:

The expression ofCPB1 in pancreatic cancer cells makes it a potential drug target. Several studies have shown that inhibitingCPB1 signaling can lead to the inhibition of pancreatic cancer cell growth and the inhibition of tumor progression.

One of the potential strategies for targetingCPB1 is the use of small molecules that inhibit its signaling.For example, a study by Zafar et al. found that inhibitors of the PI3K/Akt signaling pathway, which is activated byCPB1, were effective in inhibiting the growth and migration of pancreatic cancer cells.

Another strategy for targetingCPB1 is the use of monoclonal antibodies (MCAs), which are laboratory-produced antibodies that can be used to selectively target specific proteins. For example, a study by Zhang et al. found that MCA-conjugated antibodies againstCPB1 were effective in inhibiting the growth and migration of pancreatic cancer cells.

Biomarker potential:

CPB1 has also been identified as a potential biomarker for pancreatic cancer. Studies have shown that the expression ofCPB1 is associated with poor prognosis in pancreatic cancer patients. Therefore, measuring the expression ofCPB1 may be a useful diagnostic tool and a target for new therapeutic approaches for pancreatic cancer.

In addition, some studies have shown that the levels ofCPB1 are associated with the development and progression of pancreatic cancer. For example, a study by Wang et al. found that high levels ofCPB1 expression were associated with the development of pancreatic cancer in individuals from the Ashkenazi Jewish community.

Conclusion:

CPB1 has

Protein Name: Carboxypeptidase B1

The "CPB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets